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Treatment of hyperlipidemia reduces glomerular injury in obese Zucker
rats. 1-lyperlipidemic obese Zucker rats develop albuniinuria and spon-
taneous focal glomerulosclerosis (FGS) at an early age, despite normal
glomerular capillary pressures and nephron plasma flows. To investi-
gate the role of abnormal lipid metabolism in the pathogenesis of FGS,
pharmacologic agents were used to reduce serum lipids in male, obese
Zucker rats. Eight rats were treated from 8 to 40 weeks of age with the
cholesterol synthesis inhibitor, mevinolin (group I). A separate group of
seven obese rats was treated with the structurally-unrelated lipid
lowering agent. clofibric acid (group II). Results from these two groups
were compared to controls injected with vehicle only (group 111). Body
weight and food intake were similar in all three groups. Mevinolin
reduced both serum cholesterol and fasting triglyceride levels while
clofibric acid lowered only serum cholesterol. Urine albumin excretion
was reduced in groups land II compared to group 111. Mesangial matrix
expansion and cellularity were both reduced by mevinolin and clofibric
acid. In addition, the percent of glomeruli with focal glomerulosclerosis
was much less in groups 1(0.4 0.1%) and 11(1.3 0.7%) compared
to group III (4.6 0.7%, P < 0.05). Micropuncture studies, carried out
in separate groups of obese rats, demonstrated that mevinolin and
clofibric acid did not affect glomerular hemodynamic function. Al-
though the precise mechanism remains to be defined, these results
suggest that abnormal lipid metabolism may be important in the
pathogenesis of FGS.
Focal glomerulosclerosis (FGS) is seen in a variety of human
glomerular diseases [I]. In addition, several animal models of
chronic nonimmune-mediated glomerular disease are character-
ized by the development of FGS [2—5]. Factors important in the
pathogenesis of FGS are poorly understood. Investigations
using subtotal renal ablation in the rat have suggested that
increases in glomerular capillary pressure may contribute to the
development of FGS [3, 61. Other studies have indicated that
coagulation factors may be important in the pathogenesis of
FGS [7, 81. Recently, we demonstrated that the lipid lowering
agents mevinolin and clofibric acid ameliorated alburninuria and
reduced FGS in rats subjected to 5/6 nephrectomy [91. Glomer-
ular hemodynamic function was not altered by clofibric acid in
this model, suggesting that nonhemodynamic factors, such as
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decreased serum cholesterol, may have contributed to the
observed reduction in glomerular injury [9].
The obese Zucker rat is a model of nonimmune-mediated,
spontaneous FGS [4, 10—12]. Obesity, an autosomal recessive
trait accompanied by hyperlipidemia, develops at an early age
in Zucker rats [11, 12]. In addition, obese rats are characterized
by mild glucose intolerance ano peripheral insulin resistance
similar to that found in humans with type II diabetes [13]. These
metabolic abnormalities precede the development of albumin-
uria and glomerular injury in obese Zucker rats [4, 12]. Lean
littermates have been shown to have normal serum lipids and
normal renal structure and function [4]. We previously demon-
strated that glomerular hemodynamic function was not signifi-
cantly different in obese Zucker rats compared to lean litter-
mates [10]. Thus, nonhemodynamic factors may be important in
the pathogenesis of FGS in this model [10].
The present study was designed to investigate the role of
abnormal lipid metabolism in the pathogenesis of FGS in obese
Zucker rats. Obese rats were treated for 32 weeks with mevin-
olin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitor. Mevinolin lowered serum cholesterol ai.d
triglyceride levels, reduced albuminuria, and ameliorated FGS.
Similar results were obtained when the study was repeated
using the structurally-unrelated lipid lowering agent, clofibric
acid. Together, these results suggest that abnormalities in lipid
metabolism may be important in the pathogenesis of FGS.
Methods
Experimental design
Male, obese Zucker rats used in this study were obtained
from the Hormel Institute (University of Minnesota, Austin,
Minnesota, USA). Rats were fed standard rodent chow (Ralston
Purina Co., St. Louis, Missouri, USA), and were allowed free
access to water throughout the study. At eight weeks of age,
eight obese Zucker rats (group I) began receiving daily subcu-
taneous injections of mevinolin (Merck, Sharp, and Dohme,
West Point, Pennsylvania, USA), at a dose of 4 mg/kg body
weight. Rats were treated for 32 weeks. Eight age-matched
obese Zucker rats received injections of only the propylene
glycol vehicle and served as controls. In a separate experiment,
seven obese Zucker rats, eight weeks of age, were treated with
daily subcutaneous injections of clofibric acid (Sigma, St.
667
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Louis, Missouri, USA), 200 mg/kg body wt (group II). For this
experiment, 10 age-matched obese control rats received injec-
tions of propylene glycol vehicle only. Since the results from
the vehicle injected rats for the mevinolin and cloflbric acid
experiments were not different, the two control groups were
combined (group III) for analysis.
Fasting serum cholesterol and triglyceride levels were mea-
sured in all rats at 16, 28, and 40 weeks of age. Awake, systolic
blood pressure and 24-hour urine albumin excretion (UaibV)
were determined at 16 and 32 weeks of age. Food intake
measurements were obtained when rats were 28 weeks of age.
At 40 weeks of age, tissue was obtained for histologic studies.
Chemistries, urine albumin, and blood pressure
Serum cholesterol and triglyceride levels were obtained after
rats had been fasted for 18 hours. Blood was drawn from the
tails of rats subjected to light ether anesthesia. Serum choles-
terol was measured colorimetrically using the Trinder reaction.
Triglycerides were measured colorimetrically using a coupled
enzymatic reaction sequence with a dye reduction step. Both
cholesterol and triglycerides were measured using an autoana-
lyzer (ASTRA, Beckman Instruments, Inc., Brea, California,
USA).
A 24-hour urine collection was obtained from rats housed
individually in metabolic cages for determination of UaJbV.
During urine collection, rats were deprived of food, but had free
access to water. Urine albumin was measured using a laser
nephelometer (Hyland, Inc., Deerfield, Illinois, USA) and a
monospecific antibody to rat serum albumin (Cappel Laborato-
ries, West Chester, Pennsylvania, USA). Morning tail cuff
blood pressure measurements were obtained on awake rats that
had been trained to rest quietly in warmed restrainers [14].
Histology
Tissue for light microscopy was fixed in Zenker's solution
and stained with periodic acid-Schiff by techniques previously
described [4]. All tissue was examined in a blinded manner. A
semiquantitative scoring system was used to evaluate the extent
and severity of glomerular mesangial matrix expansion. In each
tissue specimen, 25 superficial and 25 juxtamedullary glomeruli
were scored as previously described [4]. Briefly, a score of 0 to
4+ was assigned to each glomerulus according to the proportion
of the tuft demonstrating increased mesangial matrix. The
mesangial matrix score for each tissue specimen was the sum of
individual glomerular scores multiplied by the percent of gb-
meruli with the same score. Mesangial cellularity, determined
by the proportion of the glomerulus with mesangial areas
containing four or more nuclei, was assessed in a similar
manner. The mesangial cellularity score for each tissue speci-
men was the sum of individual glomerular scores multiplied by
the percent of glomeruli with the same score. In addition, the
percent of all glomeruli with unequivocal evidence of FGS was
determined. For this determination, 182 7 glomeruli were
examined in each tissue specimen. FGS lesions were charac-
terized by scarring and collapse of a portion of the glomerular
tuft. Frequently, adhesions between the tuft and Bowman's
capsule were present (Fig. 1).
Glomerular area was estimated using a previously described
technique [151. Long- and short-axis measurements were made
on all nonsclerotic glomeruli encountered on a serpentine
course between cortex and medulla. An eyepiece micrometer at
400x magnification was used, and a total of 50 glomeruli were
measured in each tissue specimen. Area was calculated as ¼ir
ab, where a and b are long- and short-axis measurements. The
mean glomerular area was used to compare relative glomerular
size between groups, and not to represent true glomerular area.
Food intake estimates
Food intakes were estimated when rats were 28 weeks of age.
Rats were housed individually, and food was weighed daily for
six consecutive days. The amount of food consumed was
calculated for each day. The mean of the daily individual
determinations was used as an estimate of food intake. Food
intakes were expressed as grams consumed per 24 hours, per
rat.
Single nephron function studies
In order to assess the possible role of altered glomerular
hemodynamic function on the results obtained with mevinolin
and clofibric acid, micropuncture studies were carried out in
separate groups of obese Zucker rats. Eight-week-old rats were
treated with mevinolin (group IV, N = 6), clofibric acid (group
V. N = 7) or propylene glycol vehicle only (group VI, N 8) in
a manner identical to that used for groups I, II and III.
Micropuncture studies were performed when rats were 14
weeks of age, that is, before significant glomerular injury occurs
in obese Zucker rats [4, 10].
Micropuncture studies were carried out using techniques
previously described [9, 11]. Rats were not fasted prior to
micropuncture. Rats were anesthetized with sodium pentobar-
bitol (50 mg/kg body wt), and placed on a heated table. A
tracheostomy was performed and appropriate venous, arterial
and bladder cannulas were placed. Rats received a bolus
injection of Ringer's solution (0.4 to 0.5% of body wt) given
slowly over a period of 15 to 20 minutes. A solution of Ringer's
containing 25 jrCi 3H-inulin per ml was then infused at a rate of
0.5 ml/l00 g body wt/min throughout the remainder of the
study. The kidney was exposed through an abdominal incision,
cleared of perirenal tissue, immobilized in a plastic holder, and
bathed continuously with mineral oil at 37°C.
After a 45-minute stabilization period, timed proximal tubular
fluid collections were made to determine single nephron gb-
merular filtration rate (SNGFR). Proximal tubular pressure (Pr)
was measured under free-flow conditions. In a different group
of tubules, after blocking the tubular lumen with Sudan black-
colored mineral oil, stop-flow pressure (Psi) was measured.
Efferent arteriolar pressure (PE) was also determined in ran-
domly selected, efferent vascular welling points. During these
measurements, an arterial blood sample was obtained for total
protein determination and calculation of arterial oncotic pres-
sure (ITA) using the Landis-Pappenheimer equation. Blood
samples were also taken from efferent vascular welling points
for determination of efferent arteriolar protein concentration
and efferent oncotic pressure (IrE). Gbomerular capillary pres-
sure (PGC) was estimated as the sum of Psf and ITA. In all cases,
filtration pressure equilibrium was not attained, and unique
values for the gbomerular ultrafiltration coefficient (Kf) were
calculated [9, 10].
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Fig. 1. Glomeruli from mevinolin-treated obese Zucker rats showing normal architecture (A) and mesangial matrix expansion (B). Normal
glomerulus, together with a glomerulus showing mesangial expansion and focal glomerulosclerosis, in an untreated obese Zucker rat (C). Focal
glomeruloscierosis in a glomerulus from an untreated obese Zucker control (D). Focal area of increased mesangial cellularity in a glomerulus from
an untreated, obese Zucker control rat (E). Oil red 0-positive material in a glomerulus from an untreated, obese Zucker rat (F). Original
magnification: bOx, C; 200x, A, B, D and F; oil immersion, l000x, E.
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Statistical analysis
Results are expressed as mean SEM. The significance of
differences between group means was tested using one-way
analysis of variance and Scheffe's multiple comparison test.
Urine albumin data was analyzed after logarithmic transforma-
tion to normalize group variances. All differences were consid-
ered significant for P < 0.05.
Results
General characteristics
Body weights and kidney weights were similar in all groups
(Table 1). Blood pressure was slightly reduced at 16 weeks in
clofibric acid treated rats, but was not altered in rats treated
with mevinolin (Table 1). Food intakes at 28 weeks of age were
28 I g/day in group I, 26 I g/day in group II, and 28 I
glday in group III (P > 0.05).
Serum cholesterol levels were reduced by both mevinolin and
clofibric acid (Table 2). Triglycerides, on the other hand, were
reduced only in the mevinolin treated rats (Table 2).
At both 16 and 32 weeks of age, UIhV was substantially
reduced in mevinolin and clofibric acid treated rats compared to
vehicle injected controls (Table 1).
Histology
Mesangial matrix was reduced by approximately 50% in
mevinolin and clofibric acid-treated rats (Fig. I, Table 3). In all
three groups, mesangial matrix expansion was less marked in
superficial than in juxtamedullary glomeruli. However, the
reduction in mesangial matrix in groups I and II, compared to
group III, was similar in both zones.
Changes in mesangial cellularity paralleled changes in mesan-
gial matrix. Mesangial cellularity was reduced in groups I and II
compared to group Ill (Fig. I, Table 3). Mesangial cellularity
was less marked in superficial than in juxtamedullary glomeruli
in all groups. Mesangial cellularity was reduced in both super-
ficial and juxtamedullary glomeruli of groups I and II compared
to controls.
Both mevinolin and clofibric acid caused marked reductions
in the percent of glomeruli with FGS (Table 3). Mean glomer-
ular area of nonsclerotic glomeruli were similar in all three
groups (Table 3).
Table 1. The effects of mevinolin and clofibric acid on body weight, kidney weight and blood pressure in obese Zucker rats
Blood pressure mm Hg Urine albumin ,ng124 hr
Group Final body wt g Left kidney wt g 16 Weeks 32 Weeks 16 Weeks 32 Weeks
I. Mevinolin 543" 1.38° 1 j2.h 114° 2.9° 9.8"
N = 8 0.06 5 6 1.0 3.0
II. Clofibric acid 566" 1.45" 94" 128" 1.8" 24.1"N 7 0.06 5 7 0.5 8.6
III. Controls 601" 1.46" l14' 129" I 15b 466h
N = 18 0.05 3 5 2.8 6.3
a,b Shared superscripts indicate P > 0.05
Table 2. The effects of mevinolin and clofibric acid on fasting serum cholesterol and triglycerides
Cholesterol mg/cl! Triglycerides ing/dI
Group 16 Weeks 28 Weeks 40 Weeks 16 Weeks 28 Weeks 40 Weeks
I. Mevinolin 82" 84" 91" 246" 227" 277"
N=8 8 6 17 14 41
II. Clofibric acid 87" 1 I3" 83" 436b 402' 3971'N=7 12 7 54 25 17
111. Controls 116b 126h 146h 418b 450b 4055
N=18 6 10 31 27 19
a.b Shared superscripts indicate P > 0.05
Table 3. The effects of mevinolin and clofibric acid on glomerular structure
Percent glomeruli
Mesangial Mesangial with focal Glomerular area
Group expansion cellularity glomerulosclerosis % sq. microns
0.4°1. Mevinolin 38N=8
II. Clofibric acid 55"N=7
III. Controls 90
N=18
a,b Shared superscripts indicate P > 0.05
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Table 4. The effects of mevinolin and clofibric acid on single nephron function in obese Zucker rats
Kf
ni sec mm
Hg
MAP SNGFR SNPF ______
Body wt g LKwt g ,nmHg ni/mm n//mm SNFF CA gidi
______________
364 1.05 128 47.6 130 0.37 4.8 14.5 55.0 40.6 0.044
0.09 6 3.3 15 0.02 0.1 0.4 2.0 1.1 0.005
321 1.01 117 40.1 121 0.33 5.0 15.3 56.1 42.1 0.038
0.06 3 2.7 4 0.03 0.0 0.2 1.6 1.7 0.006
367 1.00 129 46.2 150 0.31 5.1 15.7 57.5 44.1 0.034
0.08 2 4.9 16 0.02 0.1 0.4 1.9 1.9 0.004
Abbreviations are: body wt, body weight; LK wt, left kidney weight; MAP, mean arterial pressure during micropuncture; SNGFR, single
nephron glomerular filtration rate; SNPF, single nephron plasma flow; SNFF, single nephron filtration fraction; CA, arterial plasma protein
concentration; ITA, arterial plasma oncotic pressure; PGC, glomerular capillary hydraulic pressure; P, mean transcapillary hydraulic pressure
difference; K1, glomerular ultrafiltration coefficient. No group means were significantly different (P > 0.05).
Single nephron function
There were no differences in body weight or kidney weight
between mevinolin, clofibric acid, and vehicle injected obese
Zucker rats subjected to micropuncture (Table 4). Although
MAP was slightly lower in clofibric acid treated rats, this
difference was not statistically significant (P = 0.06). Hemato-
crits were 48.6 1.1% in mevinolin, 44.9 1.0% in clofibric
acid, and 46.9 0.9% in vehicle-injected obese Zucker rats (P
> 0.05). Mevinolin and clofibric acid did not significantly alter
SNGFR, superficial nephron plasma flow (SNPF), GC, or Kf
(Table 4).
Discussion
Mevinolin is a specific pharmacologic inhibitor of HMG-CoA
reductase. HMG-CoA reductase is present in most mammalian
cells, and catalyzes the rate-limiting step in cholesterol synthe-
sis. Mevinolin has been shown to lower serum cholesterol
levels in humans and in experimental animals [16, 17]. Cloflbric
acid is the pharmacologically active form of the oral lipid
lowering agent, clofibrate. Clofibric acid partially blocks he-
patic release of lipoproteins, inhibits cholesterol biosynthesis,
and enhances lipoprotein lipase activity [18]. In the present
study, both of these structurally unrelated agents ameliorated
hyperlipidemia and reduced glomerular injury in obese Zucker
rats.
The effects of mevinolin and clofibric acid on triglyceride
metabolism in obese Zucker rats were somewhat different.
While mevinolin caused a substantial lowering of fasting triglyc-
eride levels, this effect was not observed with clofibric acid
administration. In contrast, both agents caused similar de-
creases in serum cholesterol levels, and both caused reductions
in UabV and FGS. Although it is possible that clofibric acid
caused triglyceride alterations that were not evident in mea-
surements of fasting triglyceride levels [19], these results sug-
gest that improved cholesterol metabolism was more closely
associated with the observed reduction in glomerular injury.
It is unlikely that mevinolin and clofibric acid reduced the
amount of FGS by altering glomerular hemodynamics. Single
nephron hemodynamic function was not affected by either
mevinolin or clofibric acid (Table 4). Thus, nonhemodynamic
effects of mevinolin and clofibric acid were most likely respon-
sible for the reduced glomerular injury observed in this study.
It is possible that reductions in serum cholesterol prevented
FGS in much the same way as reducing serum cholesterol levels
retards the development of atherosclerosis [20, 21]. Mesangial
cells have many characteristics of vascular smooth muscle cells
[221. It is possible that increased mesangial cholesterol and/or
cholesteryl ester accumulation could result in mesangial cell
proliferation analogous to vascular smooth muscle cell prolifer-
ation in atherosclerosis [23]. Indeed, the beneficial effects of the
lipid lowering agents in the present investigation were associ-
ated with reduced mesangial cellularity, as well as significantly
less mesangial matrix expansion. Thus, pharmacologic reduc-
tions in serum cholesterol may have altered deposition of
cholesterol in the glomerular mesangium, reduced mesangial
cell proliferation, and inhibited the development of FGS. It is
also possible that direct or indirect inhibition of platelets, or
other factors important in the development of atherosclerosis,
may have contributed to the amelioration of glomerular injury
observed in mevinolin and clofibric acid-treated obese Zucker
rats.
There is other experimental evidence to suggest that abnor-
malities in cholesterol metabolism may be important in the
pathogenesis of FGS. For example, dietary cholesterol supple-
mentation has been shown to cause an increase in the amount of
age-associated FGS in rats, rabbits, and guinea pigs [24—271. In
addition, lipid deposits have been observed in the mesangium of
rats with chronic puromycin aminonucleoside nephrosis [2],
and halofenate, a clofibric acid analog, reduced the amount of
FGS in this model [28]. The results of the present investigation,
together with previous findings, suggest that abnormalities in
lipid metabolism may influence the development and progres-
sion of glomerular injury.
The precise mechanisms by which abnormalities in lipid
metabolism may lead to glomerular injury remain to be deter-
mined. However, the potential importance of these observa-
tions is underscored by the almost invariable finding of hyper-
lipidemia in patients with chronic renal insufficiency [29].
Patients with the nephrotic syndrome, for example, have marked
hyperlipidemia that may be only partially corrected by inducing
a remission [30]. Diabetes, which accounts for approximately
25% of all end-stage renal disease in the United States [31], is
frequently accompanied by abnormalities in lipid metabolism
[32]. The present studies using the obese Zucker rat, a model of
both type II diabetes and spontaneous FGS, underscore the
potential role of lipid abnormalities in the pathogenesis of
diabetic nephropathy. Finally, decreased renal function itself is
frequently associated with abnormalities in lipid metabolism
[33]. Thus, a clearer understanding of the mechanisms whereby
Group
IV. Mevinolin
N= 6
V. Clofibric acid
N=7
VI. Sham
N= 8
A 'DCC j;
mm Hg
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lipid abnormalities may lead to glomerular injury could suggest
important new treatment strategies for patients with renal
insufficiency.
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